Immupharma Regulatory News (IMM)

12 July 2017

Grant of Options

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces the approval of the grant of options over 1,400,000 ordinary shares of 10p each ("Ordinary Shares") to certain of its non-executive Directors representing 1.06% of ImmuPharma's Ordinary Shares and total voting rights on a fully diluted basis. The exercise price for these options is 56.75p pence being the closing middle market share price on 11 July 2017. The options will vest after three years and are exercisable between three and ten years from the date of grant.

The amount of options granted to non-executive Directors are summarised in the following table:

Following this grant of all options on the above date, the total number of share options outstanding will be 8,233,850 representing 6.2% of ImmuPharma's Ordinary Shares and total voting rights on a fully diluted basis.

Messrs McCarthy, di Muzio and Mery currently have the following interests in issued Ordinary Shares:

Following the grant of the options referred to above, Messrs McCarthy, di Muzio and Mery will have the following interests in options over the Company's Ordinary Shares:

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

Ends